[Comment] Could enpatoran add to our therapeutic toolbox in SLE?

Medical progress in treating systemic lupus erythematosus (SLE) has historically lagged behind other rheumatic diseases, leaving a significant gap in available therapeutic options for patients.

According to a commentary published in The Lancet on May 9, 2026, SLE remains a clinically and serologically heterogeneous condition, which contributes to the difficulty in developing effective treatments.

The publication notes that only two new therapies have been licensed for the treatment of SLE since the 1950s.

Current Therapeutic Limitations

The two newly licensed therapies target specific biological pathways: B-cell activating factor (BAFF) and type-1 interferon receptors.

While these represent advancements, the report indicates they are often insufficient when used as monotherapy.

Beyond clinical efficacy, these treatments face barriers related to cost and varied availability across different global regions.

Impact on Patient Outcomes

Because of the limited number of targeted options, there is a continuing over-reliance on corticosteroids to manage the disease.

Patient outcomes are further negatively affected by a heavy reliance on broad immunosuppression.

This reliance on broad-spectrum agents and steroids often occurs because more precise, targeted therapies are either unavailable or inadequate on their own.

Evaluating New Options

The slow pace of innovation has created a pressing need for additional tools in the clinical arsenal for managing SLE.

In the May 9, 2026, commentary, the discussion centers on whether a new option, enpatoran, could potentially add to the existing therapeutic toolbox for those living with the condition.

The introduction of new targeted therapies is viewed as a necessary step to reduce the burden of broad immunosuppression and the long-term risks associated with corticosteroid use.